The effectiveness of the Russian Sputnik V vaccine against coronavirus made 92% on the results of the interim analysis of the data of the third phase of the clinical trials as the Russian Direct Investment Fund reported on vaccine’s Twitter.
“The first interim data analysis of the Sputnik V vaccine against Covid-19 phase III clinical trials in the Russian Federation demonstrated 92% efficacy,” the message said.
The fund noted that during the third phase of the trials the efficiency estimation was held among over 16,000 volunteers in 21 days after vaccination of placebo.
Moreover, the publication of the first results of Sputnik V trials allows starting mass vaccination in the upcoming weeks.
On August 11, President of Russia Vladimir Putin reported that the first vaccine against coronavirus was registered in Russia.
The vaccine would be produced by N. F. Gamaleya Federal Research Center for Epidemiology & Microbiology and the Russian Binnopharm Company. According to Murashko, finalizing takes place of the technical regulations for scaling of production at the number of Russian productions.
Earlier, the Health Ministry of Russia released to the civil circulation the first batch of Sputnik V vaccine against the coronavirus.